Yes, that’s the 21-patient Servier trial I was referring to—your link quotes 1/5/13 as the “end date,” so data will presumably be available in early 2013.
Inasmuch as this is an open-label trial and Servier recently agreed to an upgrade of the Servier/XOMA phase-3 program in uveitis, it’s reasonable to surmise that the results in the 21-patient trial will be reasonably strong.
News 
Market Data 
Discover 
